Bilirubin as a surrogate marker of dolutegravir-associated CNS adverse events

Authors
Category Primary study
JournalTopics in Antiviral Medicine
Year 2020
This article has no abstract
Epistemonikos ID: 8963c4e088dcf9626185dd3d04df70cee3e66920
First added on: Feb 12, 2025